Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Cyclopropyl Scaffold: A Generalist for Marketed Drugs

Author(s): Mo-Ran Sun, Hong-Liang Li, Meng-Yu Ba, Weyland Cheng, Hai-Liang Zhu* and Yong-Tao Duan*

Volume 21, Issue 2, 2021

Published on: 29 July, 2020

Page: [150 - 170] Pages: 21

DOI: 10.2174/1389557520666200729161150

Price: $65

Abstract

In recent decades, much attention has been given to cyclopropyl scaffolds, which commonly exist in natural products and synthetic organic molecules. Clinical drug molecules with cyclopropyl rings are an area of focus in therapeutic research due to their interesting chemical properties and unique pharmacology activity. These molecular drugs against different targets are applicable in some therapeutic treatment fields including cancer, infection, respiratory disorder, cardiovascular and cerebrovascular diseases, dysphrenia, nervous system disorders, endocrine and metabolic disorders, skin disease, digestive disorders, urogenital diseases, otolaryngological and dental diseases, and eye diseases. This review is a guide for pharmacologists who are in search of valid preclinical/clinical drug compounds where the progress, from 1961 to the present day, of approved marketed drugs containing cyclopropyl scaffold is examined.

Keywords: Cyclopropyl, clinical drug, disease, chemical property, pharmacology, activity, cancer, respiratory disorder, eye disease.

« Previous Next »
Graphical Abstract

[1]
Ebner, C.; Carreira, E.M. Cyclopropanation strategies in recent total syntheses. Chem. Rev., 2017, 117(18), 11651-11679.
[http://dx.doi.org/10.1021/acs.chemrev.6b00798] [PMID: 28467054]
[2]
Freund, A. Ueber trimethylen. J. Prakt. Chem., 1882, 26(1), 367-377.
[http://dx.doi.org/10.1002/prac.18820260125]
[3]
Wiberg, K.B. The concept of strain in organic chemistry. Angew. Chem. Int. Ed. Engl., 1986, 25(4), 312-322.
[http://dx.doi.org/10.1002/anie.198603121]
[4]
de Meijere, A. Bonding properties of cyclopropane and their chemical consequences. Angew. Chem. Int. Ed. Engl., 1979, 18(11), 809-826.
[http://dx.doi.org/10.1002/anie.197908093]
[5]
Gagnon, A.; Duplessis, M.; Fader, L. Arylcyclopropanes: Properties, synthesis and use in medicinal chemistry. Org. Prep. Proced. Int., 2010, 42(1), 1-69.
[http://dx.doi.org/10.1080/00304940903507788]
[6]
Barnes-Seeman, D.; Jain, M.; Bell, L.; Ferreira, S.; Cohen, S.; Chen, X-H.; Amin, J.; Snodgrass, B.; Hatsis, P. Metabolically stable tert-butyl replacement. ACS Med. Chem. Lett., 2013, 4(6), 514-516.
[http://dx.doi.org/10.1021/ml400045j] [PMID: 24900702]
[7]
Yu, K-L.; Sin, N.; Civiello, R.L.; Wang, X.A.; Combrink, K.D.; Gulgeze, H.B.; Venables, B.L.; Wright, J.J.K.; Dalterio, R.A.; Zadjura, L.; Marino, A.; Dando, S.; D’Arienzo, C.; Kadow, K.F.; Cianci, C.W.; Li, Z.; Clarke, J.; Genovesi, E.V.; Medina, I.; Lamb, L.; Colonno, R.J.; Yang, Z.; Krystal, M.; Meanwell, N.A. Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability. Bioorg. Med. Chem. Lett., 2007, 17(4), 895-901.
[http://dx.doi.org/10.1016/j.bmcl.2006.11.063] [PMID: 17169560]
[8]
Abe, H.; Kikuchi, S.; Hayakawa, K.; Iida, T.; Nagahashi, N.; Maeda, K.; Sakamoto, J.; Matsumoto, N.; Miura, T.; Matsumura, K.; Seki, N.; Inaba, T.; Kawasaki, H.; Yamaguchi, T.; Kakefuda, R.; Nanayama, T.; Kurachi, H.; Hori, Y.; Yoshida, T.; Kakegawa, J.; Watanabe, Y.; Gilmartin, A.G.; Richter, M.C.; Moss, K.G.; Laquerre, S.G. Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO Solvate). ACS Med. Chem. Lett., 2011, 2(4), 320-324.
[http://dx.doi.org/10.1021/ml200004g] [PMID: 24900312]
[9]
Smith, P.W.; Wyman, P.A.; Lovell, P.; Goodacre, C.; Serafinowska, H.T.; Vong, A.; Harrington, F.; Flynn, S.; Bradley, D.M.; Porter, R.; Coggon, S.; Murkitt, G.; Searle, K.; Thomas, D.R.; Watson, J.M.; Martin, W.; Wu, Z.; Dawson, L.A. New quinoline NK3 receptor antagonists with CNS activity. Bioorg. Med. Chem. Lett., 2009, 19(3), 837-840.
[http://dx.doi.org/10.1016/j.bmcl.2008.12.005] [PMID: 19117759]
[10]
Reichelt, A.; Martin, S.F. Synthesis and properties of cyclopropane-derived peptidomimetics. Acc. Chem. Res., 2006, 39(7), 433-442.
[http://dx.doi.org/10.1021/ar030255s] [PMID: 16846207]
[11]
Yoshida, Y.; Naoe, Y.; Terauchi, T.; Ozaki, F.; Doko, T.; Takemura, A.; Tanaka, T.; Sorimachi, K.; Beuckmann, C.T.; Suzuki, M.; Ueno, T.; Ozaki, S.; Yonaga, M. Discovery of (1R,2S)-2- (2,4-Dimethylpyrimidin-5-yl)oxy methy1-2-(3-fluorophenyl)-N -(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and efficacious oral orexin receptor antagonist. J. Med. Chem., 2015, 58(11), 4648-4664.
[http://dx.doi.org/10.1021/acs.jmedchem.5b00217] [PMID: 25953512]
[12]
Marson, C.M. New and unusual scaffolds in medicinal chemistry. Chem. Soc. Rev., 2011, 40(11), 5514-5533.
[http://dx.doi.org/10.1039/c1cs15119c] [PMID: 21837344]
[13]
Lerchner, A.; Machauer, R.; Betschart, C.; Veenstra, S.; Rueeger, H.; McCarthy, C.; Tintelnot-Blomley, M.; Jaton, A-L.; Rabe, S.; Desrayaud, S.; Enz, A.; Staufenbiel, M.; Paganetti, P.; Rondeau, J-M.; Neumann, U. Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg. Med. Chem. Lett., 2010, 20(2), 603-607.
[http://dx.doi.org/10.1016/j.bmcl.2009.11.092] [PMID: 19963375]
[14]
Gentles, R.G.; Ding, M.; Bender, J.A.; Bergstrom, C.P.; Grant-Young, K.; Hewawasam, P.; Hudyma, T.; Martin, S.; Nickel, A.; Regueiro-Ren, A.; Tu, Y.; Yang, Z.; Yeung, K-S.; Zheng, X.; Chao, S.; Sun, J-H.; Beno, B.R.; Camac, D.M.; Chang, C-H.; Gao, M.; Morin, P.E.; Sheriff, S.; Tredup, J.; Wan, J.; Witmer, M.R.; Xie, D.; Hanumegowda, U.; Knipe, J.; Mosure, K.; Santone, K.S.; Parker, D.D.; Zhuo, X.; Lemm, J.; Liu, M.; Pelosi, L.; Rigat, K.; Voss, S.; Wang, Y.; Wang, Y-K.; Colonno, R.J.; Gao, M.; Roberts, S.B.; Gao, Q.; Ng, A.; Meanwell, N.A.; Kadow, J.F. Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase. J. Med. Chem., 2014, 57(5), 1855-1879.
[http://dx.doi.org/10.1021/jm4016894] [PMID: 24397558]
[15]
Wu, W.; Lin, Z.; Jiang, H. Recent advances in the synthesis of cyclopropanes. Org. Biomol. Chem., 2018, 16(40), 7315-7329.
[http://dx.doi.org/10.1039/C8OB01187G] [PMID: 30229776]
[16]
Talele, T.T. The “Cyclopropyl Fragment” is a versatile player that frequently appears in preclinical/clinical drug molecules. J. Med. Chem., 2016, 59(19), 8712-8756.
[http://dx.doi.org/10.1021/acs.jmedchem.6b00472] [PMID: 27299736]
[17]
Kwong, A.D.; Kauffman, R.S.; Hurter, P.; Mueller, P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat. Biotechnol., 2011, 29(11), 993-1003.
[http://dx.doi.org/10.1038/nbt.2020] [PMID: 22068541]
[18]
Venkatraman, S.; Bogen, S.L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y.T.; Lovey, R.; Hendrata, S.; Huang, Y.; Pan, W.; Parekh, T.; Pinto, P.; Popov, V.; Pike, R.; Ruan, S.; Santhanam, B.; Vibulbhan, B.; Wu, W.; Yang, W.; Kong, J.; Liang, X.; Wong, J.; Liu, R.; Butkiewicz, N.; Chase, R.; Hart, A.; Agrawal, S.; Ingravallo, P.; Pichardo, J.; Kong, R.; Baroudy, B.; Malcolm, B.; Guo, Z.; Prongay, A.; Madison, V.; Broske, L.; Cui, X.; Cheng, K.C.; Hsieh, Y.; Brisson, J.M.; Prelusky, D.; Korfmacher, W.; White, R.; Bogdanowich-Knipp, S.; Pavlovsky, A.; Bradley, P.; Saksena, A.K.; Ganguly, A.; Piwinski, J.; Girijavallabhan, V.; Njoroge, F.G. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J. Med. Chem., 2006, 49(20), 6074-6086.
[http://dx.doi.org/10.1021/jm060325b] [PMID: 17004721]
[19]
Rosenquist, Å.; Samuelsson, B.; Johansson, P-O.; Cummings, M.D.; Lenz, O.; Raboisson, P.; Simmen, K.; Vendeville, S.; de Kock, H.; Nilsson, M.; Horvath, A.; Kalmeijer, R.; de la Rosa, G.; Beumont-Mauviel, M. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J. Med. Chem., 2014, 57(5), 1673-1693.
[http://dx.doi.org/10.1021/jm401507s] [PMID: 24446688]
[20]
Eley, T.; Garimella, T.; Li, W.; Bertz, R.J. Asunaprevir: An HCV protease inhibitor with preferential liver distribution. Clin. Pharmacol. Drug Dev., 2017, 6(2), 195-200.
[http://dx.doi.org/10.1002/cpdd.315] [PMID: 28263460]
[21]
McCauley, J.A.; McIntyre, C.J.; Rudd, M.T.; Nguyen, K.T.; Romano, J.J.; Butcher, J.W.; Gilbert, K.F.; Bush, K.J.; Holloway, M.K.; Swestock, J.; Wan, B-L.; Carroll, S.S.; DiMuzio, J.M.; Graham, D.J.; Ludmerer, S.W.; Mao, S-S.; Stahlhut, M.W.; Fandozzi, C.M.; Trainor, N.; Olsen, D.B.; Vacca, J.P.; Liverton, N.J. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. J. Med. Chem., 2010, 53(6), 2443-2463.
[http://dx.doi.org/10.1021/jm9015526] [PMID: 20163176]
[22]
Harper, S.; McCauley, J.A.; Rudd, M.T.; Ferrara, M.; DiFilippo, M.; Crescenzi, B.; Koch, U.; Petrocchi, A.; Holloway, M.K.; Butcher, J.W.; Romano, J.J.; Bush, K.J.; Gilbert, K.F.; McIntyre, C.J.; Nguyen, K.T.; Nizi, E.; Carroll, S.S.; Ludmerer, S.W.; Burlein, C.; DiMuzio, J.M.; Graham, D.J.; McHale, C.M.; Stahlhut, M.W.; Olsen, D.B.; Monteagudo, E.; Cianetti, S.; Giuliano, C.; Pucci, V.; Trainor, N.; Fandozzi, C.M.; Rowley, M.; Coleman, P.J.; Vacca, J.P.; Summa, V.; Liverton, N.J. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med. Chem. Lett., 2012, 3(4), 332-336.
[http://dx.doi.org/10.1021/ml300017p] [PMID: 24900473]
[23]
Arasappan, A.; Bennett, F.; Bogen, S.L.; Venkatraman, S.; Blackman, M.; Chen, K.X.; Hendrata, S.; Huang, Y.; Huelgas, R.M.; Nair, L.; Padilla, A.I.; Pan, W.; Pike, R.; Pinto, P.; Ruan, S.; Sannigrahi, M.; Velazquez, F.; Vibulbhan, B.; Wu, W.; Yang, W.; Saksena, A.K.; Girijavallabhan, V.; Shih, N.Y.; Kong, J.; Meng, T.; Jin, Y.; Wong, J.; McNamara, P.; Prongay, A.; Madison, V.; Piwinski, J.J.; Cheng, K.C.; Morrison, R.; Malcolm, B.; Tong, X.; Ralston, R.; Njoroge, F.G. Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor. ACS Med. Chem. Lett., 2010, 1(2), 64-69.
[http://dx.doi.org/10.1021/ml9000276] [PMID: 24900178]
[24]
Jiang, Y.; Andrews, S.W.; Condroski, K.R.; Buckman, B.; Serebryany, V.; Wenglowsky, S.; Kennedy, A.L.; Madduru, M.R.; Wang, B.; Lyon, M.; Doherty, G.A.; Woodard, B.T.; Lemieux, C.; Geck Do, M.; Zhang, H.; Ballard, J.; Vigers, G.; Brandhuber, B.J.; Stengel, P.; Josey, J.A.; Beigelman, L.; Blatt, L.; Seiwert, S.D. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J. Med. Chem., 2014, 57(5), 1753-1769.
[http://dx.doi.org/10.1021/jm400164c] [PMID: 23672640]
[25]
Campoli-Richards, D.M.; Monk, J.P.; Price, A.; Benfield, P.; Todd, P.A.; Ward, A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs, 1988, 35(4), 373-447.
[http://dx.doi.org/10.2165/00003495-198835040-00003 ] [PMID: 3292209]
[26]
Renau, T.E.; Sanchez, J.P.; Shapiro, M.A.; Dever, J.A.; Gracheck, S.J.; Domagala, J.M. Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria. J. Med. Chem., 1995, 38(15), 2974-2977.
[http://dx.doi.org/10.1021/jm00015a021] [PMID: 7636859]
[27]
Miller, D. Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections. Clin. Ophthalmol., 2008, 2(1), 77-91.
[http://dx.doi.org/10.2147/OPTH.S1666] [PMID: 19668391]
[28]
Perry, C.M.; Barman Balfour, J.A.; Lamb, H.M. Gatifloxacin. Drugs, 1999, 58(4), 683-696.
[http://dx.doi.org/10.2165/00003495-199958040-00010] [PMID: 10551438]
[29]
Fukuoka, Y.; Ikeda, Y.; Yamashiro, Y.; Takahata, M.; Todo, Y.; Narita, H. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob. Agents Chemother., 1993, 37(3), 384-392.
[http://dx.doi.org/10.1128/AAC.37.3.384] [PMID: 8460909]
[30]
Yoo, B.K.; Triller, D.M.; Yong, C-S.; Lodise, T.P. Gemifloxacin: A new fluoroquinolone approved for treatment of respiratory infections. Ann. Pharmacother., 2004, 38(7-8), 1226-1235.
[http://dx.doi.org/10.1345/aph.1E003] [PMID: 15187209]
[31]
Takahata, M.; Mitsuyama, J.; Yamashiro, Y.; Yonezawa, M.; Araki, H.; Todo, Y.; Minami, S.; Watanabe, Y.; Narita, H. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob. Agents Chemother., 1999, 43(5), 1077-1084.
[http://dx.doi.org/10.1128/AAC.43.5.1077] [PMID: 10223917]
[32]
Sitafloxacin: DU 6859, DU 6859A, Gracevit, sitafloxacin hydrate. Drugs R D., 2003, 4(1), 61-68.
[http://dx.doi.org/10.2165/00126839-200304010-00013 ] [PMID: 12568642]
[33]
Vila, J.; Hebert, A.A.; Torrelo, A.; López, Y.; Tato, M.; García-Castillo, M.; Cantón, R. Ozenoxacin: A review of preclinical and clinical efficacy. Expert Rev. Anti Infect. Ther., 2019, 17(3), 159-168.
[http://dx.doi.org/10.1080/14787210.2019.1573671 ] [PMID: 30686133]
[34]
Patel, S.S.; Benfield, P. Nevirapine. Clin. Immunother., 1996, 6(4), 307-317.
[http://dx.doi.org/10.1007/BF03259093]
[35]
Ren, J.; Milton, J.; Weaver, K.L.; Short, S.A.; Stuart, D.I.; Stammers, D.K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure, 2000, 8(10), 1089-1094.
[http://dx.doi.org/10.1016/S0969-2126(00)00513-X] [PMID: 11080630]
[36]
Daluge, S.M.; Good, S.S.; Faletto, M.B.; Miller, W.H.; St Clair, M.H.; Boone, L.R.; Tisdale, M.; Parry, N.R.; Reardon, J.E.; Dornsife, R.E.; Averett, D.R.; Krenitsky, T.A. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother., 1997, 41(5), 1082-1093.
[http://dx.doi.org/10.1128/AAC.41.5.1082] [PMID: 9145874]
[37]
Birnbaum, J.; Kahan, F.M.; Kropp, H.; MacDonald, J.S. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am. J. Med., 1985, 78(6A), 3-21.
[http://dx.doi.org/10.1016/0002-9343(85)90097-X] [PMID: 3859213]
[38]
Hoy, S.M. Tecovirimat: First global approval. Drugs, 2018, 78(13), 1377-1382.
[http://dx.doi.org/10.1007/s40265-018-0967-6] [PMID: 30120738]
[39]
Lauderdale, T.L.; Shiau, Y.R.; Lai, J.F.; Chen, H.C.; King, C.H.R. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob. Agents Chemother., 2010, 54(3), 1338-1342.
[http://dx.doi.org/10.1128/AAC.01197-09] [PMID: 20065058]
[40]
Park, H-S.; Kim, H-J.; Seol, M-J.; Choi, D-R.; Choi, E-C.; Kwak, J-H. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob. Agents Chemother., 2006, 50(6), 2261-2264.
[http://dx.doi.org/10.1128/AAC.01407-05] [PMID: 16723601]
[41]
Lipworth, B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet, 2005, 365(9454), 167-175.
[http://dx.doi.org/10.1016/S0140-6736(05)17708-3 ] [PMID: 15639300]
[42]
Hohlfeld, J.M.; Schoenfeld, K.; Lavae-Mokhtari, M.; Schaumann, F.; Mueller, M.; Bredenbroeker, D.; Krug, N.; Hermann, R. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: A randomized placebo-controlled trial. Pulm. Pharmacol. Ther., 2008, 21(4), 616-623.
[http://dx.doi.org/10.1016/j.pupt.2008.02.002] [PMID: 18374614]
[43]
Labelle, M.; Belley, M.; Gareau, Y.; Gauthier, J.Y.; Guay, D.; Gordon, R.; Grossman, S.G.; Jones, T.R.; Leblanc, Y.; McAuliffe, M.; McFarlane, C.; Masson, P.; Metters, K.M.; Ouimet, N.; Patrick, D.H.; Piechuta, H.; Rochette, C.; Sawyer, N.; Xiang, Y.B.; Pickett, C.B.; Ford-Hutchinson, A.W.; Zamboni, R.J.; Young, R.N. Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enxyme induction. Bioorg. Med. Chem. Lett., 1995, 5(3), 283-288.
[http://dx.doi.org/10.1016/0960-894X(95)00023-M]
[44]
Kajinami, K.; Takekoshi, N.; Saito, Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev., 2003, 21(3), 199-215.
[http://dx.doi.org/10.1111/j.1527-3466.2003.tb00116.x ] [PMID: 12931254]
[45]
Suzuki, M.; Iwasaki, H.; Fujikawa, Y.; Kitahara, M.; Sakashita, M.; Sakoda, R. Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem., 2001, 9(10), 2727-2743.
[http://dx.doi.org/10.1016/S0968-0896(01)00198-5 ] [PMID: 11557359]
[46]
Capodanno, D.; Dharmashankar, K.; Angiolillo, D.J. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev. Cardiovasc. Ther., 2010, 8(2), 151-158.
[http://dx.doi.org/10.1586/erc.09.172] [PMID: 20136601]
[47]
Na, Y-G.; Byeon, J-J.; Wang, M.; Huh, H.W.; Son, G-H.; Jeon, S-H.; Bang, K-H.; Kim, S-J.; Lee, H-J.; Lee, H-K.; Cho, C-W. Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor. Int. J. Nanomed., 2019, 14, 1193-1212.
[http://dx.doi.org/10.2147/IJN.S190426] [PMID: 30863054]
[48]
Caplain, H.; Donat, F.; Gaud, C.; Necciari, J. Pharmacokinetics of clopidogrel. Semin. Thromb. Hemost., 1999, 25(Suppl. 2), 25-28.
[PMID: 10440419]
[49]
Beau, B.; Mahieux, F.; Paraire, M.; Laurin, S.; Brisgand, B.; Vitou, P. Efficacy and safety of rilmenidine for arterial hypertension. Am. J. Cardiol., 1988, 61(7), 95D-102D.
[http://dx.doi.org/10.1016/0002-9149(88)90474-2] [PMID: 2894168]
[50]
Luccioni, R. Pharmaco-epidemiologic evaluation of rilmenidine in 18,235 hypertensive patients. Presse Med., 1995, 24(38), 1857-1864.
[PMID: 8545441]
[51]
Bertrand, G.; Gross, R.; Petit, P.; Loubatières-Mariani, M.M.; Ribes, G. Evidence for a direct stimulatory effect of cibenzoline on insulin secretion in rats. Eur. J. Pharmacol., 1992, 214(2-3), 159-163.
[http://dx.doi.org/10.1016/0014-2999(92)90113-I] [PMID: 1516637]
[52]
Tabuchi, Y.; Yashiro, H.; Hoshina, S.; Asano, S.; Takeguchi, N. Cibenzoline, an ATP-sensitive K(+) channel blocker, binds to the K(+)-binding site from the cytoplasmic side of gastric H(+),K(+)-ATPase. Br. J. Pharmacol., 2001, 134(8), 1655-1662.
[http://dx.doi.org/10.1038/sj.bjp.0704422] [PMID: 11739241]
[53]
Manoury, P.M.; Binet, J.L.; Rousseau, J.; Lefèvre-Borg, F.; Cavero, I.G. Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases. J. Med. Chem., 1987, 30(6), 1003-1011.
[http://dx.doi.org/10.1021/jm00389a008] [PMID: 2884312]
[54]
Tamiya, J.; Dyck, B.; Zhang, M.; Phan, K.; Fleck, B.A.; Aparicio, A.; Jovic, F.; Tran, J.A.; Vickers, T.; Grey, J.; Foster, A.C.; Chen, C. Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(11), 3328-3332.
[http://dx.doi.org/10.1016/j.bmcl.2008.04.025] [PMID: 18445525]
[55]
Auclair, A.L.; Martel, J.C.; Assié, M.B.; Bardin, L.; Heusler, P.; Cussac, D.; Marien, M.; Newman-Tancredi, A.; O’Connor, J.A.; Depoortère, R. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology, 2013, 70, 338-347.
[http://dx.doi.org/10.1016/j.neuropharm.2013.02.024 ] [PMID: 23499664]
[56]
Bonnaud, B.; Cousse, H.; Mouzin, G.; Briley, M.; Stenger, A.; Fauran, F.; Couzinier, J.P. 1-Aryl-2-(aminomethyl)cyclopropane-carboxylic acid derivatives. A new series of potential antidepressants. J. Med. Chem., 1987, 30(2), 318-325.
[http://dx.doi.org/10.1021/jm00385a013] [PMID: 3806614]
[57]
Brodie, R.R.; Chasseaud, L.F.; Taylor, T. Concentrations of N-descyclopropylmethylprazepam in whole-blood, plasma, and milk after administration of prazepam to humans. Biopharm. Drug Dispos., 1981, 2(1), 59-68.
[http://dx.doi.org/10.1002/bdd.2510020107] [PMID: 6786389]
[58]
Barzaghi, N.; Leone, L.; Monteleone, M.; Tomasini, G.; Perucca, E. Pharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects. Eur. J. Drug Metab. Pharmacokinet., 1989, 14(4), 293-298.
[http://dx.doi.org/10.1007/BF03190114] [PMID: 2633923]
[59]
Ulrich, S.; Ricken, R.; Adli, M. Tranylcypromine in mind (Part I): Review of pharmacology. Eur. Neuropsychopharmacol., 2017, 27(8), 697-713.
[http://dx.doi.org/10.1016/j.euroneuro.2017.05.007 ] [PMID: 28655495]
[60]
Schulz-Fincke, J.; Hau, M.; Barth, J.; Robaa, D.; Willmann, D.; Kürner, A.; Haas, J.; Greve, G.; Haydn, T.; Fulda, S.; Lübbert, M.; Lüdeke, S.; Berg, T.; Sippl, W.; Schüle, R.; Jung, M. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. Eur. J. Med. Chem., 2018, 144, 52-67.
[http://dx.doi.org/10.1016/j.ejmech.2017.12.001] [PMID: 29247860]
[61]
Yong, Z.; Gao, X.; Ma, W.; Dong, H.; Gong, Z.; Su, R. Nalmefene reverses carfentanil-induced loss of righting reflex and respiratory depression in rats. Eur. J. Pharmacol., 2014, 738, 153-157.
[http://dx.doi.org/10.1016/j.ejphar.2014.05.044] [PMID: 24886878]
[62]
Ingman, K.; Hagelberg, N.; Aalto, S.; Någren, K.; Juhakoski, A.; Karhuvaara, S.; Kallio, A.; Oikonen, V.; Hietala, J.; Scheinin, H. Prolonged central μ-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology, 2005, 30(12), 2245-2253.
[http://dx.doi.org/10.1038/sj.npp.1300790] [PMID: 15956985]
[63]
Viola, D.; Cappagli, V.; Elisei, R. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Future Oncol., 2013, 9(8), 1083-1092.
[http://dx.doi.org/10.2217/fon.13.128] [PMID: 23902240]
[64]
Carlos, G.; Anforth, R.; Clements, A.; Menzies, A.M.; Carlino, M.S.; Chou, S.; Fernandez-Peñas, P. Cutaneous toxic effects of BRAF inhibitors alone and in combination With MEK inhibitors for metastatic melanoma. JAMA Dermatol., 2015, 151(10), 1103-1109.
[http://dx.doi.org/10.1001/jamadermatol.2015.1745 ] [PMID: 26200476]
[65]
Dufour, R.; Daumar, P.; Mounetou, E.; Aubel, C.; Kwiatkowski, F.; Abrial, C.; Vatoux, C.; Penault-Llorca, F.; Bamdad, M. BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: A prospective role in resistance to Olaparib. Sci. Rep., 2015, 5, 12670.
[http://dx.doi.org/10.1038/srep12670] [PMID: 26234720]
[66]
Shumaker, R.C.; Aluri, J.; Fan, J.; Martinez, G.; Thompson, G.A.; Ren, M. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin. Drug Investig., 2014, 34(9), 651-659.
[http://dx.doi.org/10.1007/s40261-014-0217-y] [PMID: 25022720]
[67]
Ghasemiyeh, P.; Azadi, A.; Daneshamouz, S.; Heidari, R.; Azarpira, N.; Mohammadi-Samani, S. Cyproterone acetate-loaded nanostructured lipid carriers: Effect of particle size on skin penetration and follicular targeting. Pharm. Dev. Technol., 2019, 24(7), 812-823.
[http://dx.doi.org/10.1080/10837450.2019.1596133 ] [PMID: 30889371]
[68]
Hoskin, P.J.; Hanks, G.W. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs, 1991, 41(3), 326-344.
[http://dx.doi.org/10.2165/00003495-199141030-00002 ] [PMID: 1711441]
[69]
Cordery, S.F.; Husbands, S.M.; Bailey, C.P.; Guy, R.H.; Delgado-Charro, M.B. Simultaneous transdermal delivery of buprenorphine hydrochloride and naltrexone hydrochloride by iontophoresis. Mol. Pharm., 2019, 16(6), 2808-2816.
[http://dx.doi.org/10.1021/acs.molpharmaceut.9b00337 ] [PMID: 31070927]
[70]
Ding, H.X.; Liu, K.K.C.; Sakya, S.M.; Flick, A.C.; O’Donnell, C.J. Synthetic approaches to the 2011 new drugs. Bioorg. Med. Chem., 2013, 21(11), 2795-2825.
[http://dx.doi.org/10.1016/j.bmc.2013.02.061] [PMID: 23623674]
[71]
Augeri, D.J.; Robl, J.A.; Betebenner, D.A.; Magnin, D.R.; Khanna, A.; Robertson, J.G.; Wang, A.; Simpkins, L.M.; Taunk, P.; Huang, Q.; Han, S.P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G.E.; Egan, D.M.; Marcinkeviciene, J.; Chang, S.Y.; Biller, S.A.; Kirby, M.S.; Parker, R.A.; Hamann, L.G. Discovery and preclinical profile of Saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2005, 48(15), 5025-5037.
[http://dx.doi.org/10.1021/jm050261p] [PMID: 16033281]
[72]
Singh, J.A. Emerging therapies for gout. Expert Opin. Emerg. Drugs, 2012, 17(4), 511-518.
[http://dx.doi.org/10.1517/14728214.2012.736488] [PMID: 23126250]
[73]
Williams, M.T.; Gutierrez, A.; Vorhees, C.V. Effects of acute exposure of permethrin in adult and developing sprague-dawley rats on acoustic startle response and brain and plasma concentrations. Toxicol. Sci., 2018, 165(2), 361-371.
[http://dx.doi.org/10.1093/toxsci/kfy142] [PMID: 29893952]
[74]
Siegfried, S. La?Titia Bouérat, D. Calcipotriol cream: A review of its use in the management of psoriasis. J. Dermatolog. Treat., 2009, 17(6), 327-337.
[75]
Nagase, H.; Yamamoto, N.; Yata, M.; Ohrui, S.; Okada, T.; Saitoh, T.; Kutsumura, N.; Nagumo, Y.; Irukayama-Tomobe, Y.; Ishikawa, Y.; Ogawa, Y.; Hirayama, S.; Kuroda, D.; Watanabe, Y.; Gouda, H.; Yanagisawa, M. Design and synthesis of potent and highly selective orexin 1 receptor antagonists with a morphinan skeleton and their pharmacologies. J. Med. Chem., 2017, 60(3), 1018-1040.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01418 ] [PMID: 28051300]
[76]
Hayashi, M.; Hirota, T.; Saeki, H.; Nakagawa, H.; Ishiuji, Y.; Matsuzaki, H.; Tsunemi, Y.; Kato, T.; Shibata, S.; Sugaya, M.; Sato, S.; Tada, Y.; Doi, S.; Miyatake, A.; Ebe, K.; Noguchi, E.; Ebihara, T.; Amagai, M.; Esaki, H.; Takeuchi, S.; Furue, M.; Tamari, M. Genetic polymorphism in the TRAF3IP2 gene is associated with psoriasis vulgaris in a Japanese population. J. Dermatol. Sci., 2014, 73(3), 264-265.
[http://dx.doi.org/10.1016/j.jdermsci.2013.11.012 ] [PMID: 24373565]
[77]
Richards, S.L.; Balanay, J.A.G.; White, A.V.; Hope, J.; Vandock, K.; Byrd, B.D.; Reiskind, M.H. Insecticide susceptibility screening against Culex and Aedes (Diptera: Culicidae) mosquitoes from the United States. J. Med. Entomol., 2018, 55(2), 398-407.
[http://dx.doi.org/10.1093/jme/tjx198] [PMID: 29186579]
[78]
Earnshaw, S.R.; Klok, R.M.; Iyer, S.; McDade, C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness-a cost-effectiveness analysis. Aliment. Pharmacol. Ther., 2010, 31(8), 911-921.
[http://dx.doi.org/10.1111/j.1365-2036.2010.04244.x ] [PMID: 20096019]
[79]
Watari, R.; Matsuda, A.; Ohnishi, S.; Hasegawa, H. Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting μ-opioid receptor antagonist. Drug Metab. Pharmacokinet., 2019, 34(2), 126-133.
[http://dx.doi.org/10.1016/j.dmpk.2018.12.002] [PMID: 30770183]
[80]
Kajbaf, M.; Jahanshahi, M.; Lamb, J.H.; Gorrod, J.W.; Naylor, S. Bioanalytical applications of tandem mass spectrometry in the in vitro metabolism of the anticholinergic drug cimetropium bromide to detect differences in species metabolism. Xenobiotica, 1992, 22(6), 641-655.
[http://dx.doi.org/10.3109/00498259209053127] [PMID: 1441588]
[81]
Chen, X.H.; Zhang, B.W.; Li, H.; Peng, X.X. Myo-inositol improves the host’s ability to eliminate balofloxacin-resistant Escherichia coli. Sci. Rep., 2015, 5, 10720.
[http://dx.doi.org/10.1038/srep10720] [PMID: 26030712]
[82]
Caruso, S.; Mauro, D.; Maiolino, L.; Grillo, C.; Rapisarda, A.M.C.; Cianci, S. Effects of combined oral contraception containing drospirenone on premenstrual exacerbation of Meniere’s disease: Preliminary study. Eur. J. Obstet. Gynecol. Reprod. Biol., 2018, 224, 102-107.
[http://dx.doi.org/10.1016/j.ejogrb.2018.03.015] [PMID: 29573626]
[83]
Huang, W.; Zhang, N.; Hua, H.; Liu, T.; Tang, Y.; Fu, L.; Yang, Y.; Ma, X.; Zhao, Y. Preparation, pharmacokinetics and pharmacodynamics of ophthalmic thermosensitive in situ hydrogel of betaxolol hydrochloride. Biomed. Pharmacother., 2016, 83, 107-113.
[http://dx.doi.org/10.1016/j.biopha.2016.06.024] [PMID: 27470557]
[84]
Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A.L.; Myrianthopoulos, V.; Mikros, E.; Tarricone, A.; Musacchio, A.; Roe, S.M.; Pearl, L.; Leost, M.; Greengard, P.; Meijer, L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem., 2004, 47(4), 935-946.
[http://dx.doi.org/10.1021/jm031016d] [PMID: 14761195]
[85]
Sasagawa, T.; Yamada, T.; Nakagawa, T.; Tsujioka, T.; Takahashi, Y.; Kawakita, N.; Nonaka, K.; Nakamura, A. In vitro metabolism of dexamethasone cipecilate, a novel synthetic corticosteroid, in human liver and nasal mucosa. Xenobiotica, 2011, 41(10), 874-884.
[http://dx.doi.org/10.3109/00498254.2011.582894] [PMID: 21657966]
[86]
Barnes, K.B.; Hamblin, K.A.; Richards, M.I.; Laws, T.R.; Vente, A.; Atkins, H.S.; Harding, S.V. Demonstrating the protective efficacy of the novel fluoroquinolone finafloxacin against an inhalational exposure to Burkholderia pseudomallei. Antimicrobial Agents Chemotherapy, 2017, 61(7)
[http://dx.doi.org/10.1128/AAC.00082-17]

Rights & Permissions Print Cite
Article Metrics
91
World Chagas Disease
© 2024 Bentham Science Publishers | Privacy Policy